The growing development effort into evaluating RNA as a target for novel therapeutics could lead to a novel type of therapy to treat heart failure, according to the clinical-stage German biotech, Cardior Pharmaceuticals GmbH.
New Mechanisms: Cardior’s Non-Coding RNA Therapeutic For Heart Failure
MicroRNAs Also Of Interest To Other Biotechs
Germany’s Cardior is conducting clinical studies with an antisense oligonucleotide which inhibits a cellular microRNA believed to be involved in the pathology of heart failure, and is attracting attention from other pharma companies interested in the potential of this new mechanism of action.
More from Cardiovascular
More from Therapy Areas
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.